Just wondering ;) Why not design a head-head comparison to answer a pragmatic clinical question
Constipation rates are 12-27% depending on dose
Accordingly, the researchers constructed an anticancer food atlas to quantify the number of active anticancer molecules contained in each food, which can be used to formulate precise nutritional programs for cancer patients (257)

Monitor for: Gastrointestinal symptoms: Nausea or vomiting (occurring in approximately 1520% of patients at therapeutic doses per FDA labeling) Abdominal pain or cramping Diarrhea or constipation Loss of appetite or early satiety Bloating or abdominal distension Hypoglycemia indicators (particularly if you take other diabetes medications): Trembling, shakiness, or sweating Rapid heartbeat or palpitations Dizziness, lightheadedness, or confusion Hunger or irritability Headache or blurred vision Injection site reactions: Bruising, swelling, or hematoma formation Persistent pain or tenderness Redness or warmth suggesting inflammation Hardness or nodule formation under the skin Semaglutide's mechanism involves glucose-dependent insulin secretion, meaning hypoglycemia risk is generally low when used as monotherapy
Rebuilding the gastrointestinal lining and blood-brain barrier
Orlistat has been connected to rare cases of liver injury, while naltrexone-bupropion may cause mental health changes such as worsening depression or anxiety and suicidal thoughts